Peptide data sheet
Cagrilintide
GLP-1 · AM833 · Cagrilintide
Verdict
promisingThe promising label reflects genuine human trial data from the CagriSema program on body-weight endpoints; on its own, cagrilintide is an investigational research-grade peptide that is not FDA-approved and whose long-term picture is still open.
By MrPepTalks Editorial
Reviewed for scientific accuracy · research information, not medical advice
Last updated Reviewed
Quick answer
Cagrilintide (AM833) is a long-acting amylin-analog peptide commonly researched for appetite and body-weight endpoints. It is best known as the amylin half of CagriSema, an investigational combination with semaglutide that has real human trial data behind it. Cagrilintide is not FDA-approved; effects in humans are still being studied.
- Class
- Long-acting amylin-analog peptide (investigational)
- Half-life
- roughly 7 to 8 days (reported, supporting once-weekly research dosing)
- FDA status
- Not FDA-approved. Cagrilintide is an investigational research-grade peptide studied in clinical trials; it is sold for laboratory research use only and is not a finished prescription product.
- WADA banned?
- No
Which form actually works?
Injectable (subcutaneous)
Promising
The form used across the clinical trials and the CagriSema program. It carries essentially all of the human research context, and the reported side effects people discuss come from this route.
Standalone (cagrilintide alone)
Unproven
People also ask about cagrilintide on its own rather than paired with semaglutide. There is early human data here, but far less than for the combination, so the standalone picture is thinner than the CagriSema headlines suggest.
Third-Party Testing & Certificate of Analysis (COA)
A certificate of analysis (COA) is a lab document that reports what a specific batch of material actually contains. Reputable research suppliers publish one for every batch, tied to a lot number you can match against the vial you received.
- HPLC — purity
- High-performance liquid chromatography reports purity as a percentage: how much of the sample is the intended compound rather than impurities.
- Mass spectrometry (MS) — identity
- Mass spectrometry confirms identity by measuring the sample's molecular mass, so it matches the peptide the label names.
It also matters who ran the test. In-house results come from the seller's own lab; an independent third-party lab has no stake in the result, so its COA generally carries more weight. Look for a named testing laboratory, a batch or lot number, and a test date that lines up with the vial in hand.
New to reading one? This guide walks through a COA line by line: how to read a peptide COA.
Sources
- Lau DCW, Overgaard RV, Erichsen L, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, 2021.
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet, 2021.
- Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet, 2023.
- PubChem Compound Summary for CID 171397054, Cagrilintide — National Library of Medicine (NCBI).
Related peptides
All GLP-1 →Frequently asked questions
No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.